Thrombosis News and Research

Latest Thrombosis News and Research

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that results from three phase III studies evaluating the use of continuous REVLIMID(lenalidomide) treatment in newly diagnosed multiple myeloma (MM) patients or maintenance treatment with lenalidomide following autologous stem cell transplant were published online in the May 10, 2012 edition of the New England Journal of Medicine.

11 May 2012

Preclinical evidence demonstrates link between psoriasis and cardiovascular disease

The link between psoriasis and cardiovascular events has been observed for years, however the mechanics were unknown. For the first time, Case Western Reserve University School of Medicine researchers have discovered preclinical evidence demonstrating that the inflammatory skin disease leads to cardiovascular disease. Further, the research demonstrated that aggressive reversal of psoriasis reduces the cardiovascular risk as well.

11 May 2012

Janssen submits XARELTO sNDA with FDA to reduce risk of stent thrombosis in ACS patients

Janssen Research & Development, LLC announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO, an oral anticoagulant, to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome.

10 May 2012

Rutin may inhibit formation of blood clots

A compound called rutin, commonly found in fruits and vegetables and sold over the counter as a dietary supplement, has been shown to inhibit the formation of blood clots in an animal model of thrombosis.

9 May 2012

Pall in-line filters can reduce severe complications, length of hospital stay in PICU

A recently published clinical study on infusion therapy indicates in-line filters from Pall Corporation can reduce severe complications and the length of a patient's stay in the pediatric intensive care unit.

From Pall Corporation 8 May 2012

Alnylam first quarter revenues decrease to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2012, and company highlights.

4 May 2012

Large-scale, patient-specific simulations of blood function

Having a virtual copy of a patient's blood in a computer would be a boon to researchers and doctors. They could examine a simulated heart attack caused by blood clotting in a diseased coronary artery and see if a drug like aspirin would be effective in reducing the size of such a clot.

3 May 2012

TA during PCI provides long-term outcomes for patients with acute STEMI

New research confirms thrombus aspiration (TA) during percutaneous coronary intervention (PCI) in patients with acute ST-segment elevation myocardial infarction (STEMI) provides long-term outcomes similar to conventional intervention with bare-metal or drug-eluting stents.

3 May 2012

CSI third quarter revenues increase 5% to $21.2 million

Cardiovascular Systems, Inc. (CSI), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fiscal third quarter ended March 31, 2012.

3 May 2012

EKOS launches two landmark clinical studies on pulmonary embolism

EKOS Corporation today announced the launch of two more landmark clinical studies named SEATTLE I & II, intended to further establish the safety and efficacy of its unique, ultrasound-accelerated thrombolysis in treating patients with life-threatening pulmonary embolism.

3 May 2012

ASH report urges federal agencies to invest in 7 distinct areas of research

The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.

25 Apr 2012

Nordion announces additional TheraSphere Phase III trial for HCC

Nordion Inc., a leading provider of products and services for the prevention, diagnosis and treatment of disease, today announced an additional randomized, multi-centre Phase III clinical trial for TheraSphere, Nordion's yttrium-90 (Y-90) glass microsphere treatment for liver cancer.

24 Apr 2012

Orthopaedic research studies in the Journal of Bone and Joint Surgery

Below are highlights of orthopaedic research studies appearing in the April 18th issue of the Journal of Bone and Joint Surgery (JBJS), as well as the issue's full Table of Contents.

21 Apr 2012

First study to examine soda's effect on stroke risk

Researchers from Cleveland Clinic's Wellness Institute and Harvard University have found that greater consumption of sugar-sweetened and low-calorie sodas is associated with a higher risk of stroke. Conversely, consumption of caffeinated or decaffeinated coffee was associated with a lower risk.

21 Apr 2012

Perivascular fat tissue may influence onset of atherosclerosis

Researchers at UC have confirmed that fat surrounding the outside of arteries in humans-particularly the left coronary artery-may influence the onset of coronary artery disease, or atherosclerosis, which is the leading cause of death in the U.S.

21 Apr 2012

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive results from its Phase I clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.

21 Apr 2012

Depression may increase risk of peripheral artery disease

Depression may be associated with an increased risk of arterial narrowing in the legs and pelvis, a condition known as peripheral artery disease (PAD), according to research presented at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology 2012 Scientific Sessions in Chicago.

21 Apr 2012

HDAC9 gene can lead to obesity-induced body fat dysfunction

Cardiac researchers at the University of Cincinnati (UC) have found that a certain cellular pathway is linked to obesity-related disorders, like diabetes, heart disease and fatty liver disease.

20 Apr 2012

AcelRx commences dosing in second ARX-01 Phase 3 clinical trial for acute post-operative pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported dosing of the first patient in the second of three planned Phase 3 studies that will form the basis of a planned New Drug Application for the Sufentanil NanoTab PCA System, ARX-01.

12 Apr 2012

Japanese MHLW approves Abbott's XIENCE PRIME Everolimus Eluting Coronary Stent System

Abbott today announced it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the next-generation XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

9 Apr 2012